Loading news...
Heartflow (NASDAQ: HTFL) executives highlighted record revenue, accelerating adoption of its platform, and expanding reimbursement support during the company's fourth-quarter 2025 earnings call, while also initiating 2026 guidance and outlining product and clinical milestones expected over the next year. Fourth-quarter results and 2026 outlook HeartFlow reported fourth-quarter revenue of $49.1 million, up 40% year over year.
HeartFlow delivered 40% sales growth in 2025, with revenue surpassing $176 million and strong Q4 momentum. 2026 guidance targets 25% revenue growth to $218–222 million, with gross margins rising to 80–81% and further mid-term upside to 85%. HearthFlow's AI-driven CAD diagnostic platform is gaining adoption, supported by FDA-cleared next-generation algorithms and a proprietary CT image database.
HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript
Three presentations at ACC reinforce Heartflow's AI-powered technology predicts MACE, drives superior lipid outcomes and results in cost-effective care First patient enrolled in p ioneering N AVIGATE - PCI Registry assessing impact of Heartflow PCI Navigator on clinical strategy, efficiency and physician confidence across 5,000 patients MOUNTAIN VIEW, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced new clinical evidence and a landmark registry launch that together advance the company's vision of transforming CAD management across every stage of the patient journey.
Bamco Inc. NY purchased a new stake in shares of Heartflow, Inc. (NASDAQ: HTFL) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 1,237,506 shares of the company's stock, valued at approximately $41,654,000. Bamco Inc. NY owned about 1.45% of Heartflow at the end of the
Capital International Investors purchased a new stake in shares of Heartflow, Inc. (NASDAQ: HTFL) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,297,423 shares of the company's stock, valued at approximately $43,671,000. Capital International Investors owned 1.56% of Heartflow
HeartFlow, Inc. (HTFL) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley Technology, Media & Telecom Conference. The presentation will take place in San Francisco, CA, on Tuesday, March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET.
2025 US IPOs emerged out of a tumultuous April with strong price momentum going into the summer. US IPOs under $100 million in proceeds continued to perform poorly in 2025 after also struggling in 2024, with the less than $50 million issues declining 18.4% this year compared to a 17.1% decline last year. The strong performance of US technology IPOs during the first half of 2025 set the stage nicely for more issuers to go public during the second half of the year.
MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026.
Heartflow, Inc. (NASDAQ: HTFL - Get Free Report) Director Julie Cullivan sold 8,000 shares of Heartflow stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $27.32, for a total value of $218,560.00. Following the completion of the transaction, the director owned 36,413 shares of the company's stock, valued
Heartflow, Inc. (NASDAQ: HTFL - Get Free Report) reached a new 52-week low during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $25.36 and last traded at $26.42, with a volume of 575570 shares trading hands. The stock had previously closed at $27.30. Specifically, CEO John C.M.
We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. We recently initiated a position in Axon Enterprise. We exited our successful investment in Exact Sciences Corporation after Abbott Laboratories announced it was acquiring the company for approximately $23 billion in cash.
Heartflow's (NASDAQ: HTFL - Get Free Report) lock-up period is set to end on Wednesday, February 4th. Heartflow had issued 16,666,667 shares in its public offering on August 8th. The total size of the offering was $316,666,673 based on an initial share price of $19.00. After the end of Heartflow's lock-up period, restrictions preventing major shareholders
Baillie Gifford and Co. bought a new position in Heartflow, Inc. (NASDAQ: HTFL) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 3,005,998 shares of the company's stock, valued at approximately $101,182,000. Baillie Gifford and Co. owned 3.60% of Heartflow as of its most recent filing
HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis is now covered by Aetna across all lines of business, including Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans.
MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
Jeffrey Lightcap, a member of the Board of Directors of HeartFlow (HTFL 2.00%), acquired 40,000 common shares in an open-market transaction valued at $1,053,680 on Dec. 16, 2025; see SEC Form 4 filing.